High‐dose non‐sedating antihistamines are used insufficiently in chronic urticaria patients treated with omalizumab
Abstract Background The lifetime prevalence of chronic urticaria (CU) is 0.5%–1%. In some patients with CU, symptomatic control is not achieved with non‐sedating second‐generation H1 antihistamines (nsAH1) alone, even with quadrupled standard doses as recommended in international guidelines. In thes...
Gespeichert in:
| Hauptverfasser: | , , , , , |
|---|---|
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Wiley
2021-12-01
|
| Schriftenreihe: | Clinical and Translational Allergy |
| Schlagworte: | |
| Online-Zugang: | https://doi.org/10.1002/clt2.12085 |
| Tags: |
Keine Tags, Fügen Sie das erste Tag hinzu!
|